Systematic Review: Opioid Treatment for Chronic Back Pain: Prevalence, Efficacy, and Association with Addiction
Overview
Authors
Affiliations
Background: The prevalence, efficacy, and risk for addiction for persons receiving opioids for chronic back pain are unclear.
Purpose: To determine the prevalence of opioid treatment, whether opioid medications are effective, and the prevalence of substance use disorders among patients receiving opioid medications for chronic back pain.
Data Sources: English-language studies from MEDLINE (1966-March 2005), EMBASE (1966-March 2005), Cochrane Central Register of Controlled Clinical Trials (to 4th quarter 2004), PsychInfo (1966-March 2005), and retrieved references.
Study Selection: Articles that studied an adult, nonobstetric sample; used oral, topical, or transdermal opioids; and focused on treatment for chronic back pain.
Data Extraction: Two investigators independently extracted data and determined study quality.
Data Synthesis: Opioid prescribing varied by treatment setting (range, 3% to 66%). Meta-analysis of the 4 studies assessing the efficacy of opioids compared with placebo or a nonopioid control did not show reduced pain with opioids (g, -0.199 composite standardized mean difference [95% CI, -0.49 to 0.11]; P = 0.136). Meta-analysis of the 5 studies directly comparing the efficacy of different opioids demonstrated a nonsignificant reduction in pain from baseline (g, -0.93 composite standardized mean difference [CI, -1.89 to -0.03]; P = 0.055). The prevalence of lifetime substance use disorders ranged from 36% to 56%, and the estimates of the prevalence of current substance use disorders were as high as 43%. Aberrant medication-taking behaviors ranged from 5% to 24%.
Limitations: Retrieval and publication biases and poor study quality. No trial evaluating the efficacy of opioids was longer than 16 weeks.
Conclusions: Opioids are commonly prescribed for chronic back pain and may be efficacious for short-term pain relief. Long-term efficacy (> or =16 weeks) is unclear. Substance use disorders are common in patients taking opioids for back pain, and aberrant medication-taking behaviors occur in up to 24% of cases.
Kim D, Lee J, Lee Y, Yang C, Han C, Ha I J Clin Med. 2025; 14(4).
PMID: 40004733 PMC: 11856646. DOI: 10.3390/jcm14041204.
and Opioid Marketing to Veterans: Lessons for Military and Veterans Healthcare.
Haddock C, Elliott L, Kolodny A, Kaipust C, Poston W, Oliva J Healthcare (Basel). 2025; 13(4).
PMID: 39997310 PMC: 11855145. DOI: 10.3390/healthcare13040434.
Chronic and Acute Pain and Adverse Economic Outcomes in a 9/11-Exposed Cohort.
Brite J, Maqsood J, Yu S, Alper H, Cone J Int J Environ Res Public Health. 2024; 21(11.
PMID: 39595757 PMC: 11593883. DOI: 10.3390/ijerph21111490.
Reilly E, Kelly M, Grigorian H, Waring M, Quigley K, Hogan T JMIR Form Res. 2024; 8:e56437.
PMID: 39514264 PMC: 11584538. DOI: 10.2196/56437.
A genome-wide Association study of the Count of Codeine prescriptions.
Song W, Lam M, Liu R, Simona A, Weiner S, Urman R Sci Rep. 2024; 14(1):22780.
PMID: 39354046 PMC: 11445378. DOI: 10.1038/s41598-024-73925-4.